Redeye provides its comments on yesterday's news that InDex Pharmaceuticals discontinues the development of cobitolimod and will not proceed...
Redeye update its view on InDex following the year-end report and with the current circumstances we see an interesting opportunity in the sh...
Redeye makes minor adjustements to its valuation of InDex Pharmaceuticals following the announcement of anticipated end of Q1 2024 cash posi...
Redeye sees a new investment case in InDex Pharmaceuticals following the discontinuation of CONCLUDE.
Redeye leaves its initial comments in response to InDex Pharmaceuticals' announcement regarding the discontinuation of the Phase III program...
Redeye believes Q2 was quite eventful for InDex Pharmaceuticals, with the highlight being a USD50m deal struck with Viatris.
Redeye endorses yesterday evenings news that InDex Pharmaceuticals have entered into a USD50m licensing agreement with Viatris Japan to deve...
Redeye comments on InDex Pharmaceuticals following its Q1 2023 report.
Watch the replay from InDex Pharmaceuticals' business update on May 9.
Redeye endorses the positive results announced by InDex Pharmaceuticals regarding the PK study in patients with moderate to severe UC, repre...
Redeye leaves its comments on InDex following the company’s Q4 report.
Redeye leaves its comments on InDex Pharmaceuticals following its Q3 2022 report.
Redeye leaves a short comment following yesterday's news that a permanent CEO will take office in January 2023.
Redeye revisits its assessment of InDex Pharmaceuticals ahead of the blinded interim analysis of CONCLUDE’s first induction study to choose ...
Redeye comments on InDex Pharmaceuticals following its Q2 2022 report.
Redeye leaves its comments on InDex Pharmaceuticals following its Q1 2022 report.
Redeye leaves a comment on InDex Pharmaceuticals following its Capital Markets Day, where the company announced it estimates a 2027 launch o...
Redeye leaves its comment on InDex following the announcement of its year-end report.
Yesterday the FDA announced safety concerns towards JAK inhibitors following a review of a large randomized safety clinical trial.
Redeye leaves its view on InDex Pharmaceuticals following the announcement of its Q2 report.
